Hanif Esmail

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4444401/publications.pdf

Version: 2024-02-01

516215 476904 1,304 31 16 29 h-index citations g-index papers 32 32 32 2093 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nature Medicine, 2016, 22, 1090-1093.	15.2	166
2	Subclinical Tuberculosis Diseaseâ€"A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. Clinical Infectious Diseases, 2021, 73, e830-e841.	2.9	143
3	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respiratory Medicine, the, 2020, 8, 395-406.	5.2	128
4	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine, the, 2015, 3, 190-200.	5.2	122
5	Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E964-E973.	3.3	96
6	Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discovery Today, 2012, 17, 514-521.	3.2	87
7	The Immune Response to <i>Mycobacterium tuberculosis</i> ii HIV-1-Coinfected Persons. Annual Review of Immunology, 2018, 36, 603-638.	9.5	85
8	Tuberculosis Infectiousness and Host Susceptibility. Journal of Infectious Diseases, 2017, 216, S636-S643.	1.9	65
9	The Wonder Years: What Can Primary School Children Teach Us About Immunity to Mycobacterium tuberculosis?. Frontiers in Immunology, 2018, 9, 2946.	2.2	64
10	Tuberculosis is changing. Lancet Infectious Diseases, The, 2017, 17, 359-361.	4.6	49
11	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	0.8	33
12	Tuberculosis transmission during the subclinical period: could unrelated cough play a part?. Lancet Respiratory Medicine, the, 2018, 6, 244-246.	5.2	32
13	Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. European Respiratory Journal, 2020, 55, 1901957.	3.1	30
14	Mind the gap – Managing tuberculosis across the disease spectrum. EBioMedicine, 2022, 78, 103928.	2.7	30
15	From latent to patent: rethinking prediction of tuberculosis. Lancet Respiratory Medicine, the, 2017, 5, 243-244.	5.2	26
16	Screening for tuberculosis: time to move beyond symptoms. Lancet Respiratory Medicine, the, 2019, 7, 202-204.	5.2	22
17	Spotting the old foeâ€"revisiting the case definition for TB. Lancet Respiratory Medicine,the, 2019, 7, 199-201.	5.2	19
18	Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate. Journal of Infection, 2021, 82, 276-316.	1.7	16

#	Article	IF	CITATIONS
19	Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy. Annals of the American Thoracic Society, 2017, 14, 621-623.	1.5	13
20	Is MRSA admission bacteraemia community-acquired? A case control study. Journal of Infection, 2008, 56, 163-170.	1.7	12
21	Recent progress in understanding immune activation in the pathogenesis in HIV–tuberculosis co-infection. Current Opinion in HIV and AIDS, 2018, 13, 455-461.	1.5	12
22	Tuberculosis prevalence: beyond the tip of the iceberg. Lancet Respiratory Medicine, the, 2022, 10, 537-539.	5.2	11
23	QuantiFERON conversion following tuberculin administration is common in HIV infectionÂand relates to baseline response. BMC Infectious Diseases, 2016, 16, 545.	1.3	8
24	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. F1000Research, 2020, 9, 1109.	0.8	8
25	A threat to decentralised care for drug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2020, 8, 950-952.	5.2	6
26	Cardio-Thoracic Ratio Is Stable, Reproducible and Has Potential as a Screening Tool for HIV-1 Related Cardiac Disorders in Resource Poor Settings. PLoS ONE, 2016, 11, e0163490.	1.1	5
27	Elevated Nâ€terminal prohormone of brain natriuretic peptide among persons living with HIV in a South African periâ€urban township. ESC Heart Failure, 2020, 7, 3246-3251.	1.4	4
28	Individualising therapy for drug-sensitive tuberculosis. Lancet Respiratory Medicine, the, 2019, 7, 834-835.	5.2	2
29	Following Guidelines for Drug-Resistant Tuberculosis: "Yes, it's a challenge― Frontiers in Tropical Diseases, 2021, 2, .	0.5	1
30	Before the whistle blows: developing new paradigms in tuberculosis screening to maximise benefit and minimise harm. Wellcome Open Research, 0, 6, 8.	0.9	0
31	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. BMJ Open, 2021, 11, e052885.	0.8	O